Skip to main content
. 2021 Jun 7;74(3):1660–1673. doi: 10.1002/hep.31708

TABLE 4.

Studies Reported in clinicaltrials.gov Investigating the Use of Rifaximin in Cirrhosis

Endpoints Number of Studies
Prevention of complications of cirrhosis
SBP 4
CHE 3
Decompensated cirrhosis 2
HE in patients with transjugular intrahepatic portosystemic shunts 2
ACLF* 1
Variceal bleeding 1
Renal failure 1
Persistent HE 1
Other
Portal pressure 2
Systemic inflammation 1
B‐cell dysregulation 1
Portal vein thrombosis 1
Quality of life 1
*

Associated with simvastatin.